EICHORPublic-registry site landscape for NCT02638909, “Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies”, a Colorectal Adenocarcinoma study sponsored by Criterium, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02638909 (registry record) |
| Study title | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies |
| Official title | A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies |
| Sponsor | Criterium, Inc. |
| Condition(s) | Colorectal Adenocarcinoma; Cholangiocarcinoma; Pancreatic Adenocarcinoma; Hepatocellular Adenocarcinoma |
| Phase | PHASE2 |
| Listed sites | 6 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT02638909.
Eichor generates a preliminary site-risk snapshot for NCT02638909 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Colorectal Adenocarcinoma trials
← Eichor home · All tracked trials · Colorectal Adenocarcinoma studies · Weekly briefs
